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Abstract
Background: Neuroblastoma is the most common pediatric solid tumor of the sympathetic nervous system.
Development of improved predictive tools for patients stratification is a crucial requirement for neuroblastoma
therapy. Several studies utilized gene expression-based signatures to stratify neuroblastoma patients and
demonstrated a clear advantage of adding genomic analysis to risk assessment. There is little overlapping among
signatures and merging their prognostic potential would be advantageous. Here, we describe a new strategy to
merge published neuroblastoma related gene signatures into a single, highly accurate, Multi-Signature Ensemble
(MuSE)-classifier of neuroblastoma (NB) patients outcome.
Methods: Gene expression profiles of 182 neuroblastoma tumors, subdivided into three independent datasets,
were used in the various phases of development and validation of neuroblastoma NB-MuSE-classifier. Thirty three
signatures were evaluated for patients’ outcome prediction using 22 classification algorithms each and generating
726 classifiers and prediction results. The best-performing algorithm for each signature was selected, validated on
an independent dataset and the 20 signatures performing with an accuracy > = 80% were retained.
Results: We combined the 20 predictions associated to the corresponding signatures through the selection of the
best performing algorithm into a single outcome predictor. The best performance was obtained by the Decision
Table algorithm that produced the NB-MuSE-classifier characterized by an external validation accuracy of 94%.
Kaplan-Meier curves and log-rank test demonstrated that patients with good and poor outcome prediction by the
NB-MuSE-classifier have a significantly different survival (p < 0.0001). Survival curves constructed on subgroups of
patients divided on the bases of known prognostic marker suggested an excellent stratification of localized and
stage 4s tumors but more data are needed to prove this point.
Conclusions: The NB-MuSE-classifier is based on an ensemble approach that merges twenty heterogeneous,
neuroblastoma-related gene signatures to blend their discriminating power, rather than numeric values, into a
single, highly accurate patients’ outcome predictor. The novelty of our approach derives from the way to integrate
the gene expression signatures, by optimally associating them with a single paradigm ultimately integrated into a
single classifier. This model can be exported to other types of cancer and to diseases for which dedicated
databases exist.
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Neuroblastoma is the most common pediatric solid
tumor, deriving from ganglionic lineage precursors of the
sympathetic nervous system [1]. It is diagnosed during
infancy and shows notable heterogeneity with regard to
histology and clinical behavior, ranging from rapid pro-
gression associated with metastatic spread and poor clini-
cal outcome to spontaneous, or therapy-induced
regression into benign ganglioneuroma. Age at diagnosis,
stage, histology, DNA index, chromosomal aberrations,
and amplification of the N-myc proto-oncogene (MYCN)
are clinical and molecular risk factors commonly com-
bined to classify patients into high, intermediate and low
risk subgroups on which current therapeutic strategy is
based. About fifty percent of high risk patients die despite
treatment making the exploration of new and more effec-
tive strategies for improving stratification mandatory [2].
The availability of genomic profiles improved our prog-
nostic ability in many types of cancers including neuro-
blastoma [3]. Several groups have developed gene
expression-based approaches to stratify neuroblastoma
patients [4-10]. One approach for patients stratification is
to apply feature selection techniques to the patients’ data-
sets to derive gene expression signatures representative of
either biological processes related to tumor progression
(biology-driven), such as tumor hypoxia [11,12], risk esti-
mation (risk-driven) [9] or unsupervised clustering. Several
groups used gene expression-based approaches to stratify
neuroblastoma patients. Prognostic gene signatures were
described and neuroblastoma classifiers were trained to
predict the risk class and/or patients ‘outcome [4-10].
Prognostic gene expression signatures have often similar
performances despite the lack of gene overlapping suggest-
ing that they relate to a common biological feature but
derive from a highly variable environment [13]. Combina-
tion of the information contained in these signatures
should improve the accuracy and/or the predictive power
suggesting the potential application of ensemble learning
approaches to increase not only the accuracy of the classifi-
cation, but also the confidence of the results. Ensemble
methods were originally developed to enhance classification
performance [14] and have been recently applied to bio-
markers identification and feature selection [15]. The gen-
eral idea of this family of techniques consists in combining
lots of different models in a global, more robust, model.
The task of combining existing neuroblastoma gene expres-
sion signatures is rather complex because they were
designed by biology or risk-driven approaches, hence with
different finalities and applicability. Furthermore, these sig-
natures were derived using different platforms and datasets
thus preventing a straightforward integration. The problem
of merging signatures or datasets was recently addressed in
breast cancer where it was shown that multiple signatures
can lead to robust prognostic when combined to clinical
variables and large databases of gene expression [16].
Furthermore, Nuyten et al. demonstrated the relevance of
combining biological gene expression signatures into an
independent predictor for outcome in breast cancer
patients [17]. Recently, Fan et al. [18] reported the genera-
tion of a prognostic model combining hundreds of gene
expression signatures to clinical-pathological factors utiliz-
ing the Least Absolute Shrinkage and Selection Operator
method and a Cox proportional hazards approach.
These results raised the question as to whether we
could design an ensemble-based learning approach suita-
ble for integrating gene expression signatures of neuro-
blastomas tumors where patients stratification is critical
for the choice of treatment. Each tumor type has unique
biological an clinical attributes and the best performing
approaches must be designed accordingly. The potential
problem of merging previously established signatures is
that their implementation takes them out of the context
in which they were generated in terms of experimental
platform, dataset, paradigm and finality. We addressed
this issue by introducing a meticulous selection of the
algorithms for optimal performance of each signature
and by building the final single classifier on the predic-
tions rather than on gene expression values.
Results
Datasets
We aimed at integrating the prognostic information con-
tained in different neuroblastoma gene signatures hetero-
geneous with respect to the origin, feature selection,
platform and dataset. The method has been applied on a
dataset containing the gene expression profiles of 182
neuroblastoma patients (detailed in the Material and
Methods section) with a distribution of the common risk
factors (Table 1) compatible with what reported in the
literature [19]. The process can be subdivided into three
main phases (Figure 1): i) single signature classifiers gen-
eration, ii) classifiers filtering on performance figures
and, iii) NB-MuSE-classifier training and validation. The
patients’ cohort was subdivided into three independent
datasets (DS): DS1 (60 patients) to train the signatures,
DS2 (60 patients) to externally validate single-signature
classifiers and to train the NB-MuSE-classifier, and DS3
(62 patients) to externally validate the NB-MuSE-classi-
fier. The characteristics of these datasets are detailed in
the additional file 9. The signatures considered in this
work were selected from the literature by Medline search
of articles published after year 2002. We selected, by
visual screening, the articles effectively describing neuro-
blastoma gene signatures. This process led to the identifi-
cation of 39 neuroblastoma-related gene signatures,
either risk-or biology-driven, of which 33 reported a
detailed gene list and were used for the analysis
[1,4-10,12,20-43].
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Next, we evaluated the ability of each selected signature
to predict patients outcome (Figure 1). This step,
although labor intense, is critical to assess performance
of each of signatures and to filter out those poorly infor-
mative. Each of the 33 signatures was used to train
machine learning classifiers predicting neuroblastoma
patients’ outcome. A panel of 22 classification paradigms
implemented by the WEKA package (for ref see [44])
was tested for each signature to select the best possible
classifier. For each signature, the expression data of the
60 patients of dataset DS1 and the associated labels
("Alive"/"Dead”) were used to train a classifier in a
leave-one-out cross-validation (LOOCV) framework.
Thus, 726 classifiers, were generated combining 22 para-
digms and 33 signatures (Figure 1).
Phase 2. Classifiers filtering on performance figures
The following step consisted in the external validation
of every classifier for each signature by the application
of the models to the independent group of 60 patients
included in the DS2. Only the signatures performing
with an accuracy > = 80% were retained and the others
excluded from the analysis to avoid background noise.
A literature search indicated that 80% accuracy was the
lower limit considered relevant for patients’ classifica-
tion. This process filtered-out 13 signatures. Details on
Figure 1 NB-MuSE-classifier construction. Workflow of the steps involved in the construction of the NB-MuSE classifier merging the
information of 20 signatures matched to the optimal paradigm for outcome classification. The process can be subdivided into three main
phases: 1) single signature classifiers generation, 2) classifiers filtering on performance features and, 3) Neuroblastoma Multi-Signature Ensemble
classifier (NB-MuSE-classifier) training and validation. The dataset was subdivided into three different subsets: DS1(60 patients) to train the
signatures, DS2 (60 patients) to externally validate single-signature classifiers and to train the NB-MuSE-classifier, and DS3(62 patients) to
externally validate the NB-MuSE-classifier. The products of the procedure are indicated on the right side of the figure. 60 fold cross validation
refers to leave one out cross-validation (LOOCV).
Table 1 Clinical characteristics of the 182 neuroblastoma
patients analyzed
Risk groups
a Patients
b Distribution (%)
c
INSS stage 1 42 23,1
2 24 13,2
3 23 12,6
4 70 37,9
4s 23 13,2
Age at diagnosis < = 1 year 92 51,1
> 1 year 90 48,9
MYCN status Normal 153 84,1
Amplified 29 15,9
5 years survival Dead 55 29,7
Alive 127 70,3
a Common risk groups and categories stratifying neuroblastoma patients.
b The total number of patients in each group was 182. The number of
patients in each subdivision is shown.
c Percentage relative to the total number of patients in each risk group.
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gene-associated probesets are shown in the additional
file 7. There was little overlapping in gene representa-
tion among the 20 signatures composed of a total of
741 different genes of which only 128 were present in 2
or more signatures and none was common to all of
them. The most frequent gene was NTRK1 (7 signa-
tures) followed by MAPT (6 signatures), MYCN, TYMS,
VEGFA (5 signatures). These signatures differ for feature
selection criteria as shown by the biology-driven
(referred to as “biology”) or risk-driven (referred to as
“stratification”) categories listed in Table 2. Despite the
differences among these two groups, we have almost the
same number of signatures selected for each category
(Table 2). These 20 gene signatures were matched indi-
vidually with the corresponding best performing classi-
f i e ra n di n c l u d e di nt h et h i r dp h a s eo ft h ea n a l y s i s .
Classification performance for the 20 classifiers on the
independent DS2 validation set ranged from 80% to 87%
(Table 3). Twelve out of 22 paradigms were utilized
with the Multi Layer Perceptron being the most repre-
sented but there was no obvious bias towards a defined
category of algorithms. The number of genes per signa-
ture is variable (range 9-120, additional file 7) but it
does not seem influential on the predicting power.
These results generated the prediction matrix of the
selected signatures and related algorithms (Additional
file 2). In summary, the 20 signatures shown in Table 2
are, individually, the most informative for patients’ out-
come prediction in our framework and their associated
classifier was used to generate the NB-MuSE-classifier.
Phase 3. Neuroblastoma Multi-Signature Ensemble
classifier training and validation
In the third phase of our analysis we combined the 20
predictions associated with the corresponding signature
into a single outcome prediction. For this purpose, we
trained a new classifier (NB-MuSE-classifier) on the pre-
viously generated dataset containing the 20 prediction
applied to the DS2 patients. Similarly to the training
and validation step, 22 algorithms were tested to sort
out the best performing (Additional file 8). The perfor-
mance of the NB-MuSE-classifier was validated on the
independent dataset DS3. The classification accuracy of
the classifiers that were used in the process leading to
the selection of the best performing algorithm is detailed
in the Additional file 8. The best performance was
obtained by the Decision Table algorithm that produced
a classifier characterized by an external validation accu-
racy of 94% (Table 3 and Additional file 8). This accu-
racy is greater than that shown by the individual
algorithms within the context of the current framework
Table 2 Twenty signatures selected for NB-MuSE-classifier construction
Signature* PMID Reference Genes^ Category^^ Features°
Chen 19921788 [22] 50 biology MYCN
De Preter II 16989664 [1] 73 biology Neuroblast transformation
Di Pietro 19402918 [23] 33 biology Apoptosis
Fardin 20624283 [12] 62 biology Tumor hypoxia
Fransson 17044048 [24] 10 biology Chromosome 1p36
Fredlund 18780787 [25] 103 biology MYCN expression
Hahn 18607002 [26] 14 biology Histone deacetylase
McArdle 15090470 [29] 10 biology Chromosome 11q
Nevo II 15081541 [31] 13 biology CXCR4 receptor
Oe 15992370 [28] 117 biology response to NGF
Shimada 17941064 [27] 5 biology Biomarkers
Asgharzadeh 16954472 [20] 44 stratification MYCN non amplified
Benard 19383347 [21] 37 stratification age groups
De Preter I 20179214 [10] 42 stratification Risk/outcome
Fischer 16951229 [8] 17 stratification St4 vs St4s
Nevo II 19739072 [30] 95 stratification St1 vs St4
Oberthuer 17075126 [7] 108 stratification Risk/outcome
Ohira 15837623 [6] 39 stratification Risk/outcome
Vermeulen 19515614 [9] 59 stratification Risk/outcome
Wei 15466177 [4] 12 stratification Risk/outcome
* First author’s name of the paper describing the neuroblastoma-related signature used. The signatures predicate patients’ outcome with an accuracy > 80%.
^ Number of genes comprising the signature.
^^ Categories indicative of the natureof the signature. Biology: the signature discriminates biologically defined situations. Stratification: the signature discriminates
classes of tumors derived from patients’ stratification.
° Features: Indications on the nature of the biological questions asked or stratification criteria used. St = INSS stage.
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toma outcome based on gene expression profile. The
predictions of the NB-MuSE-classifier relative to that of
the individual signatures from which it was derived is
shown in the Additional file 8. In conclusion, we com-
bined the predictive power of different signatures to
merge survival categories into a single classifier predict-
ing, with high accuracy, the outcome of neuroblastoma
patients.
Evaluation of multi-step classification process
Our method included a filtering step dedicated to the
exclusion of signatures characterized by an associated
low performing classifier accuracy (< 80%) to remove
prediction results characterized by a high classification
error and/or to reduce data noise. The second classifica-
tion step was introduced to identify an optimal labeling
method. Similar conclusions could be achieved by evalu-
ating each of the two labels frequencies in the prediction
results of the single-signature classifiers. In order to
assess the need/validity of these steps, we re-applied our
method switching off the filtering step and substituting
the second classification step with label frequencies eva-
luation. As shown in Figure 2, we obtain optimal perfor-
mance figures by the inclusion of the filtering step and
the use of the second classification step. In fact, when
both filtering and classification were switched off, the
procedure achieves an accuracy of 82%, lower than most
e single-signature classifiers (Table 3). When filtering is
preserved and classification is turned off, we obtained
an accuracy of 88%. Finally, by turning off the filtering
alone, we achieve an accuracy of 91% still lower that
that obtained by the completed method. These results
demonstrate that the filtering on performances of sin-
gle-signature classifiers helps to limit classification error.
Furthermore, the application of supervised classification
approaches is required to obtain an optimal interpreta-
tion of highly complex biological data.
Clinical impact of the results
The overall- and event free-survival of the patients
divided according to the NB-MuSE-classifier are shown
in Figure 3. Kaplan-Meier curves and log-rank test
demonstrated that patients with good and poor outcome
prediction have a significantly different survival (p <
0.0001). Interestingly, the 4 mislabeled patients corre-
sponding to the 6% error of NB-MuSE-classifier on DS3
are characterized by INSS stage 4 tumors whereas 100%
accuracy was reached in classifying the outcome of
stages 1,2,3 and 4s tumors (data not shown). In agree-
ment with these results, the Kaplan Mayer curves and
log-rank test of patients with stages 1,2,3 and 4s tumors
Table 3 Merging individual classifiers into the NB-MuSE classifier
Classifier* External validation Paradigm° Function
Accuracy (%)^
Chen 85 BayesNet Learns Bayesian nets
Di Pietro 83 BayesNet Learns Bayesian nets
Fredlund 80 ClassificationViaRegression Class is binarized and one regression model is built for each class value
Asgharzadeh 83 ComplementNaiveBayes Builds a complement Näive Bayes classifier
Fransson 85 ComplementNaiveBayes Builds a complement Näive Bayes classifier
De Preter II 87 IBk k-nearest-neighbors classifier
Wei 83 IBk k-nearest-neighbors classifier
De Preter I 83 KStar Nearest neighbor with generalized distance function
Oberthuer 87 Logistic Builds linear logistic regression models
Hahn 82 MultiLayerPerceptron Backpropagation neural network
McArdle 80 MultiLayerPerceptron Backpropagation neural network
Oe 80 MultiLayerPerceptron Backpropagation neural network
Nevo II 87 NaiveBayes Standard probabilistic Näive Bayes classifier
Shimada 80 NBTree Builds a deciosion tree with Näive Bayes classifier at the leaves
Vermeulen 85 NBTree Builds a decision tree with Näive Bayes classifier at the leaves
Ohira 85 RandomForest Constructs random forest
Fischer 81 SimpleLogistic Builds linear logistic regression models with built-in attribute selection
Fardin 83 Voted Perceptron Voted perceptron algorihtm
Nevo I 80 Voted Perceptron Voted perceptron algorihtm
NB-MuSE 94 DecisonTable Builds a simple decision table majority classifier
* Classifier associated to the signature described in the paper whose first name is listed.
^ External validation on the DS3 dataset.
° Paradigms that gave the top performance in external validation.
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file 4). In contrast, MuSE signature was much less effec-
tive in stratifying st4 patients (Additional file 3). Analy-
sis of patients positive for MYCN rearrangement failed
to show a significant stratification by MuSE classifier
(Additional file 5) as expected by the small sample size.
In contrast, There was a good separation of outcome in
patients with MYCN non amplified tumors (Additional
file 6) although not as significant as that of the whole
cohort. We conclude that NB-MuSE-classifier is very
Figure 2 Evaluation of the multistep classifier generation process. The accuracy of NB-Muse classifier was measured when the selection
and/or classification steps were omitted from the procedure. The four resulting possible conditions are indicated with letters from A to C as
detailed in the figure. The percent accuracy for each condition is shown in the corresponding bar.
Figure 3 Kaplan-Meier and log-rank analysis of patients stratified according to the NB-MuSE classifier. Kaplan-Meier and log-rank analysis
for the 62 neuroblastoma patients belonging to the external validation dataset. 5-years overall survival (A) and event free survival (B) of patients
stratified according to the NB-MuSE classifier. Red and black curves represent poor and good outcome patients respectively. The p-value of the
log-rank test is shown.
Cornero et al. BMC Bioinformatics 2012, 13(Suppl 4):S13
http://www.biomedcentral.com/bmcbioinformatics/supplements/13/S4/S13
Page 6 of 12effective in stratifying neuroblastoma patients outcome.
We feel that combination of NB-MuSE-classifier with
INSS staging may be particularly accurate in predicting
the progression of the disease. However, more data
should are needed to prove this point.
Discussion
We designed a new prognostic model based on a neuro-
blastoma classifier, NB-MuSE, that predicts patients’
outcome by merging the biological and prognostic infor-
mation of published gene expression signatures, assessed
by a panel of machine learning algorithms, into a single
outcome predictor. We examined every neuroblastoma-
related signature described in the literature since 2002
without consideration for the purpose for which it was
generated or the gene expression platform used. We
took the blind screening approach to avoid biases and
to include biology-driven signatures, not previously
tested for patients stratification, in addition to risk-
based signatures. We identified 33 signatures, complete
of gene lists, suitable for our study. Patients’ outcome
was the final readout of the classifier and we had to
develop a strategy to filter out poorly information signa-
tures contributing to the background noise. We devel-
oped a multi-algorithm screening and an 80% accuracy
filter for signature selection. This essential step was
based on the overproduce-and-select approach in which
a pool of classifiers are spawned and then optimally
selected on-the-fly by monitoring accuracy of prediction
on an external dataset. We evaluated 22 machine learn-
ing algorithms for outcome prediction on the 33 signa-
tures generating 726 prediction to be evaluated for
accuracy on an independent dataset. We selected the
signatures for which we identified at least one algorithm
performing with an accuracy > 80%. Exclusion of a sig-
nature from this analysis indicated that we did not iden-
tified an algorithm capable of translating those
signatures into a predictor in our cohorts or that the
signatures were not related to patients’ outcome but it
does impact on the relevance of those genes in the con-
test of the original publication. Eleven out of thirty
three signatures were discarded. We then matched each
of the remaining 20 signatures with the best performing
algorithm among those with > 80% accuracy to generate
signature specific outcome prediction classifier. In
essence, we transformed 20 datasets each with 60
instances (patients) and numeric attributes (probesets
expression value) into one dataset with 60 instances and
20 nominal “alive” or “dead” attributes (one per selected
signature). The latter dataset could then be used as
input to train the new NB-MuSE-classifier merging all
the signature information. 22 algorithms were tested to
select the best performing which was the Decision Table
which builds a simple decision table majority classifier
and evaluates features subsets using best-first search and
can use cross validation for evaluation (for review see
[44]). Performance can be evaluated by many parameters
and there is heterogeneity in the performance of the
various algorithms tested as shown by the Additional
file 8. The Decision Table algorithm was chosen because
it showed maximal accuracy, but other parameters could
have been selected to highlight other features like sensi-
tivity or specificity. Ensemble learning approaches have
proven to exceed average classifier performance [45].
Our strategy utilizes such strategy to produce a flexible
tool merging gene expression signatures overcoming the
limitations imposed by specific environments in which
they were generated. We observed that, in the absence
of signature/algorithm filtering, the accuracy of our clas-
sifier fell below 82% a level that was lower than that
achieved by individual classifiers. The importance of
including these steps in model generation procedures to
obtain a more robust and better performing classifier
was recently reported [46]. Optimization and filtering is
quite labor intense and was not considered, for example,
in breast cancer studies merging hundred of gene
expression signatures to build classifiers [18]. The high
number of signatures available in breast cancer may bal-
ance the avoidance of filtering out poorly informative
signatures. An automated implementation of this pro-
cess can be envisioned if this approach was exported to
larger lists of signatures.
The accuracy of NB-MuSE-classifier on external valida-
tion was 94%, a value that is very high from the biologic
stand point. Although there is no logical reason why it
cannot be higher, it is difficult to envision a much better
precision from a biological standpoint considering the
variability of the experimental and clinical data. On the
other hand, there is no limit to the number of signatures
that can be derived with biological questions in mind.
Our model offers a reliablew a yt ok e e pm e r g i n gt h i s
information into an outcome classifier that will be more
robust even if not much more accurate. It is noteworthy
that the misclassified patients are grouped in the stage 4
category in agreement with the fact that prognosis of this
stage is traditionally difficult. We can speculate that com-
bination of the information of stage and NB-MuSE-clas-
sifier could be particularly effective in predicting
outcome in patients with localized tumors (stage 1-3) or
s t a g e4 sS u r v i v a la n a l y s i si ft h i sg r o u po fp a t i e n t ss u p -
ports this claim showing excellent outcome separation
superior to that observed on the whole cohort. however,
more patients will have to be tested to substantiate this
claim. Similar analysis performed on patients with
MYCN amplified tumors showed a significant outcome
stratification although not as good as that observed with
the whole cohort. We are working on strategies for com-
paring neuroblastoma gene expression dataset obtained
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address question on smaller groups of patients. We are
among the few focusing on the question of merging het-
erogeneous gene expression signatures to predict out-
come. To limit the variability, we considered only gene
expression data generated by microarray analysis of the
primary neuroblastomas using the Affymetrix platform
U133plus2 and we put together 182 primary neuroblasto-
mas, a cohort that is large for this kind of tumor. On the
other hand, there was no restriction on the technology
used to generate the signatures that turned out to be
quite heterogeneous demonstrating that our multistep
approach a is suited to work across experimental plat-
forms. This aspect is very important particularly in the
field of rare tumors, such as pediatric tumors, where it is
extremely difficult to build large homogeneous gene
expression datasets and where we may envision that the
developing signatures will be based on new experimental
platforms.
Affymetrix platform differs largely from the those used
in the studies reporting the single classifiers (e.g. two-
color gene-expression data from different technological
platforms, QPCR analyses etc.). In addition, some of the
machine learning algorithms used in the original reports
of the classifiers were not pa r to ft h ep a n e lu s e di nt h e
present study. This may explain discrepancies between
the performances of individual signatures that were pre-
viously published and that calculated in this work. The
problem of downplaying the performance of some signa-
tures is partially offset by the discovery of the prognostic
ability of other signatures, a feature not previously
shown in the original publications. However, the possi-
ble advantage of the MuSE-classifier over presently
existing classifiers cannot be easily quantified because
we took individual signatures out of their original con-
test. Table 3 shows that merging signatures into a single
classifier results in a predictor with very high accuracy
b u ti td o e sn o ti m p l yt h a tt h i sv a l u ei sm a x i m a la n d
considerations on the relative performance of MuSE ver-
sus other signatures is valid only in the contest of this
work.
The discovery of outcome prediction ability of biol-
ogy-driven signatures, never tested before for patients
stratification, is a spinoff of the process of NB-MuSE-
classifier generation. This was true for most of the biol-
ogy-driven signatures comprising about half of those in
the NB-MuSE-classifier [1,22-24,26-29,31] with the
exception of those addressing the prognostic significance
of hypoxia [12] and MYC pathway [25] that had already
been validated in patients stratification. Our data bear
direct evidence to the suggestion that the biology driven
features, measured by the gene expression signatures,
such as neuroblast transformation, apoptosis histone
deacetylase etc. (Table 2) are strongly interconnected
with the progression of the human disease and support
the need for further research in this direction [47].
Conclusions
We describe the design, generation and properties of the
NB-MuSE-classifier based on an ensemble approach that
merges heterogeneous, neuroblastoma-related gene sig-
natures to blend their discriminating power, rather than
their numeric values, into a single, highly accurate,
patients’ outcome predictor. The key of our method is
merging several datasets with numeric attributes into
one dataset with nominal “alive” or “dead” attributes.
The latter dataset could then be used as input to train
the new single classifier merging all of the prognostic
information of individual signatures through a process
which combines individual models into an ensemble of
learned models. Inevitably, the framework leading to the
MuSE-classifier implied taking the signatures out of the
original contest and matching, for example, the genes
with the Affymetrix platform probsets. Therefore, the
performances calculated by us may be different from
that originally reported and considerations on the rela-
tive performance should be limited to our framework.
On the other hand, our approach showed that signa-
tures can be successfully taken out of their contest
retaining their prognostic value. Moreover, the process
of NB-MuSE-classifier generation lead to the discovery
of the effectiveness of several biology-driven published,
signatures to predict outcome suggesting that the biolo-
gical features measured by such signatures could be
mechanistically related to the progression of the human
disease.
The novelty of our approach derives from the way to
integrate the gene expression signatures, by optimally
associating them with a single paradigm ultimately inte-
grated into a single classifier. This approach was devel-
oped on a Neuroblastoma dataset. However, this model
can be exported to other cancer types and to other dis-
eases for which dedicated databases exist.
Methods
Patients
A total of 182 neuroblastoma patients belonging to four
independent cohorts were enrolled on the bases of the
availability of gene expression profile by Affymetrix
GeneChip HG-U133plus2.0 and clinical and molecular
information. Eighty-eight patients were collected by the
Academic Medical Center (AMC; Amsterdam, Nether-
lands) [12]; 21 patients were collected by the University
Children’s Hospital, Essen, Germany and were treated
according to the German Neuroblastoma trials, either
NB97 or NB2004; 51 patients were collected at Hir-
oshima University Hospital or affiliated hospitals and
were treated according to the Japanese neuroblastoma
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Page 8 of 12protocols [48]; 22 patients were collected at Gaslini
Institute(Genoa, Italy) and were treated according to Ita-
lian AIEOP or European SIOPEN protocols. We utilized
the gene expression profiles and associated clinical para-
meters available at the R2 repository [49] (AMC and
Essen patients), at the BIT-neuroblastoma Biobank of
t h eG a s l i n iI n s t i t u t e[ 5 0 ]o fw h i c hD r .V a r e s i oc o o r d i -
nates the tumor molecular classification (Genova
patients). The instigators who deposited the data in the
R2 repository agree to use the data for this work. In
addition, we utilized the data present on the public data-
base at the Gene Expression Omnibus number
GSE16237) for Hiroshima patients [48]. Informed con-
sent was obtained in accordance with institutional poli-
cies in use in each country. In every dataset, median
follow-up was longer than 5 years and tumor stage was
defined according to the International Neuroblastoma
Staging System. The clinical characteristics of the 182
neuroblastoma tumors are listed in Table 1. Good and
poor outcome were defined as patient’s status (alive or
dead) 5 years after diagnosis. The 182 patients dataset
was randomized and divided into three subsets (DS1,
DS2, and DS3) consisting of 60, 60, and 62 patients
respectively. The characteristics of the composition of
these datasets are detailed in the Additional file 9. DS1
has been used to train the signatures, DS2 to externally
validate the single-signature classifiers and to train the
NB-MuSE-classifier, and DS3 for external validation of
the NB-MuSE-classifier.
Gene expression analysis
Gene expression profiles for the 182 tumors were
obtained by microarray experiment using Affymetrix
GeneChip HG-U133plus2.0 and the data were processed
by MAS5.0 software according Affymetrix’s guideline.
For Gaslini’s patients specimens total RNA was extracted
using Trizol (Invitrogen Life technologies, Irvine, CA)
according to the manufacturer’s instructions. RNA was
resuspended in diethyl pyrocarbonate-treated H2O
(DEPC water), the physical quality control of RNA integ-
rity was carried out by electrophoresis using Agilent
Bioanalyzer 2100 (Agilent Technologies Waldbronn, Ger-
many) and quantified by NanoDrop (NanoDrop Technol-
ogies Wilmington, Delawere USA). Total RNA was
reverse transcribed into cDNA and biotin labeled accord-
ing to the Affymetrix instructions (Affymetrix, Santa-
Clara, CA). Fragmented cRNA was used for hybridization
to Affymetrix HG-U133 Plus 2.0 arrays. Expression
values were quantified, and array quality control was per-
formed using the statistical algorithms implemented in
Affymetrix Microarray Suite 5.0. The scale factors (SF)
for all the hybridizations were within 1 SD of the mean
(SF 1-3). To asses RNA integrity quality control and
RNA digestion plot were used as implemented in the R
package “Affy”. Data of all datasets were processed by
MAS5.0 software according Affymetrix’s guideline.
Neuroblastoma gene signatures selection
The Neuroblastoma related signatures were obtained by
searching the relevant literature. Specifically, the papers
were selected from the literature by Medline search using
“neuroblastoma signatures” and “neuroblastoma expres-
sion profile” as keywords and limiting the search to arti-
cles published after year 2002. The process of selecting
out the signatures is part of the workflow and it will be
detailed in the results’ section. As a result, 33 gene signa-
tures were selected for NB-MuSE-classifier development
[1,4-10,12,20-43]. To handle signatures not based on
Affymetrix platform or lacking probesets values informa-
tion, we associated, one Affymetrix GeneChip HG-U133-
plus2.0 probesets value to each gene of the signature by
unpaired t-test on the entire dataset. The best probesets
discriminating between the “alive” and “dead” class was
picked to represent the unique gene names (Additional
file 7). This selection criterion was preferred to other
methods, such as mean, median or highest value, which
can cause loss of information at the single probesets level
and the relevance of the specific signature.
NB-MuSE-classifier design
The NB-MuSE-classifier framework, is summarized in Fig-
ure 1. The WEKA package [44] has been chosen to per-
form all the training and validation steps in our analysis.
Gene expression data have been used in linear scale in all
the computations. In the first phase, each of the selected
33 gene signatures was used to generate a classifier trained
to predict the neuroblastoma patients ‘outcome. For each
signature, the expression data of the 60 patients of dataset
DS1 and the associated 60 “true” outcome labels ("Alive"/
"Dead”) was provided to WEKA to train a classifier in a
leave-one-out cross-validation (LOOCV) framework. A
panel of 22 classification algorithms available in Weka [44]
was tested for each signature. The best performing algo-
rithm was selected for each signature according to the pre-
diction accuracy score obtained during LOOCV. As a cut-
off, we chose the top three accuracy values for each gene
signature. The next step consisted in the external valida-
tion of the selected classifiers for each signature by the
application of the models to the patients gene expression
values included in DS2. The best-performing model for
each signature was selected. If the best-performing model
had a prediction accuracy < 80%, the associated signature
was discarded and no longer considered. The decision was
made considering that relevant published classifiers have
an accuracy that is generally > 80%. Some algorithms (Bag-
ging, BayesLogisticRegression, ClassificationViaCluster,
DecisionTable, FT, IB1, J48, LWL, RandomTree, ZeroR)
did did not perform with sufficient accuracy in any of the
Cornero et al. BMC Bioinformatics 2012, 13(Suppl 4):S13
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(BayesNet, ClassificationViaRegression, ComplementNai-
veBayes, IBk, KStar, Logistic, MultiLayerPerceptron, Nai-
veBayes, NBTree, RandomForest, SimpleLogistic, Voted
Perceptron). Finally, we trained, tested, and validated the
new MuSE-classifier that, during the training phase, takes
into account the prediction produced by the application of
the selected models to DS2 to produce a single prediction
for each patient tested. A training dataset consisting of 60
patients has been assembled from the predictions gener-
ated by the 20 classifiers obtained in the previous phase
on DS2 (Additional file 1) and, likewise, a validation data-
set of 62 patients was assembled from the predictions per-
formed by the same classifiers on DS3 (Additional file 2).
Similarly to the training and validation steps performed
for each gene signature during the first phase, 22 were
tested to select optimal performance. The resulting best
performing classifier is our NB-MuSE-classifier.
Statistical analysis
The probability of overall survival (OS) and event-free
survival (EFS) was calculated using Kaplan-Meier
method, and the significance of the difference between
Kaplan-Meier curves was calculated by the log-rank test
using Prism 4.03 (GraphPad Software, Inc.). Accuracy,
specificity, and sensitivity were computed to estimate
the performance of the predictions performed in the
various steps of the study.
Additional material
Additional file 1: External validation of single signature classifiers.
Predictions performed on DS2, (60 patients) dataset by the 20 signatures
associated to the best individual classifiers selected during the first phase
are assembled in a prediction matrix and shown together with the true
outcome. A: alive, D: dead. The signatures are indicated by the initials of
the first author of the manuscript. The associated references are as
follows: DIP: Di Pietro [23], FI: Fischer [8], FR: Fredlund [25], NE I: Nevo
[30], OB: Oberhuer [7], OH: Ohira [6], WE: Wei [4], DEP I: De Preter [10],
FA: Fardin [12], OE: Oe [28], SH: Shimada [27], HA: Hahn [26], CH: Chen
[22], DEP II: De Preter II [1], BE: Benard [21], FR: Fransson [24], MCA:
McArdle [29], AS: Asgharzadeh [20], NE II: Nevo II [31], VE: Vermulen [9].
Additional file 2: NB-MuSE-classifier external validation. Predictions
performed on DS3, 62 patients dataset. The best individual-signature
classifiers selected during the first phase have been assembled in a
prediction matrix used for the external validation of the NB-MuSE-
classifier. The “Actual” column represent the true Alive/Dead label for
each patient. The “MuSE” column represent the outcome of the NB-
MuSE-classifier in external validation. A: alive, D: dead. The signatures are
indicated by the initials of the first author of the manuscript (see legend
to additional file 1).
Additional file 3: Kaplan-Meier and log-rank analysis of patients
with Stage 4 tumors stratified according to the NB-MuSE classifier.
Kaplan-Meier and log-rank analysis for INSS Stage 4 neuroblastoma
patients belonging to the external validation dataset. 5-years overall
survival (left) and event free survival (right) of patients stratified
according to the NB-MuSE classifier. Red and black curves represent poor
and good outcome patients respectively. The p-value of the log-rank test
is shown.
Additional file 4: Kaplan-Meier and log-rank analysis of patients
with localized and Stage 4s tumors stratified according to the NB-
MuSE classifier. Kaplan-Meier and log-rank analysis for INSS Stage 1,2,3
and 4s neuroblastoma patients belonging to the external validation
dataset. 5-years overall survival (left) and event free survival (right) of
patients stratified according to the NB-MuSE classifier. Red and black
curves represent poor and good outcome patients respectively. The p-
value of the log-rank test is shown.
Additional file 5: Kaplan-Meier and log-rank analysis of patients
with MYCN amplified tumors stratified according to the NB-MuSE
classifier. Kaplan-Meier and log-rank analysis for neuroblastoma patients
with MYCN amplified tumors belonging to the external validation
dataset. 5-years overall survival (left) and event free survival (right) of
patients stratified according to the NB-MuSE classifier. Red and black
curves represent poor and good outcome patients respectively. The p-
value of the log-rank test is shown.
Additional file 6: Kaplan-Meier and log-rank analysis of patients
without MYCN amplification in the tumors stratified according to
the NB-MuSE classifier. Kaplan-Meier and log-rank analysis for
neuroblastoma patients with MYCN not amplified tumors belonging to
the external validation dataset. 5-years overall survival (left) and event
free survival (right) of patients stratified according to the NB-MuSE
classifier. Red and black curves represent poor and good outcome
patients respectively. The p-value of the log-rank test is shown.
Additional file 7: Probesets and genes composition of the 20
signatures selected for building the MuSE classifier. 20 signatures,
out of 33 tested, were selected representing those performing with an
accuracy > = 80. The gene composition (Gene Name) and matching
probeset (Affymetrix) are shown. The choice of the probesets was made
according to the criteria described in the Material and Methods’ section.
The signatures are indicated by the initials of the first author of the
manuscript (see legend to additional file 1).
Additional file 8: Best performing algorithms tested to build the
MuSE classifier. The classification accuracy of the models that were
used in the process leading to the selection of the best performing
algorithm are shown together with the parameters describing the
performances of each. The 18 algorithms that gave a meaningful
separation are reported. ClassificationViaClustering, FT,
BayesLogisticRegression and MBtree did not give a significant separation
and are not shown. The algorithms are described and implemented in
WEKA package [44]. The signatures are indicated by the initials of the
first author of the manuscript (see legend to additional file 1).
Additional file 9: Characteristics of the datasets. The 182 patients
dataset was divided randomly into three subsets (DS1, DS2, and DS3)
consisting of 60, 60, and 62 patients respectively. The characteristics of
the composition of these datasets are shown. For each DS, the
composition in terms of INSS stage representation, MYCN amplification,
source of the data (AMC: Amsterdam; ESS: Essen; HI: Hiroshima; IGG:
Genoa, for details see Material and Methods), age at diagnosis and
Overall survival.
List of abbreviations
NB: Neuroblastoma; MuSE: Multi-Signature Ensemble; St: Stage; OS: overall
survival; EFS: event free survival; DS: data set; LOOCV: leave-one-out cross-
validation.
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